Evercore ISI Group Upgrades NovoCure to In-Line, Announces $33 Price Target
Portfolio Pulse from richadhand@benzinga.com
Evercore ISI Group analyst Vijay Kumar has upgraded NovoCure (NASDAQ:NVCR) from Underperform to In-Line and set a price target of $33.
July 31, 2023 | 10:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NovoCure has been upgraded by Evercore ISI Group from Underperform to In-Line, with a new price target of $33.
The upgrade from Underperform to In-Line indicates a more positive outlook on the company by the analyst. This could lead to increased investor confidence and potentially a rise in the stock price. The new price target of $33 also suggests an expected increase in the stock's value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100